Biotech Showcase 2023

Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC)

FOSTER CITY, CA--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced positive topline results from its pivotal Phase 3 MARCH study evaluating LIVMARLI® (maralixibat) oral solution in 93 patients with progressive familial intrahepatic cholestasis (PFIC) in a broad range of subtypes, age one to 17 years. The primary endpoint of improvement in pruritus severity in PFIC2 was statistically significant (p=0.0098).

“The advancement of new medications, particularly for rare diseases like PFIC, is incredibly important and provides hope to families who are in need of a treatment option that can effectively address itch, the most burdensome aspect of the disease”

The primary analysis was conducted in PFIC2 patients (n=31). The secondary analyses were evaluated in the All-PFIC cohort, which included PFIC2 as well as additional PFIC subtypes (n=64). The Full-Study population included All-PFIC as well as supplemental patients who had previously undergone surgery, had truncating mutations and other patients (n=93).

Aidoc expands cardiology solutions by bringing Us2.ai's echo AI into proprietary operating system

NEW YORK, Oct. 20, 2022 -- Aidoc, the leading provider of healthcare AI solutions, announced today a partnership with Us2.ai to bring its FDA-cleared and CE Marked AI algorithm to analyze and interpret echocardiograms (echo) into its proprietary aiOS™.

Within Aidoc's aiOS – a first-in-market operating system that can orchestrate multiple independent AI algorithms across the native workflows of various specialties – the Us2.ai algorithm can deliver a fully automated and standardized echo report to sonographers and cardiologists.

Recipients of the 2022 WIA Demeter Award of Excellence Announced

Topsfield, Mass., (August 25, 2022) – Three exceptional women have been named recipients of the 2022 Women in Agribusiness (WIA) Demeter Award of Excellence – Diane Allemang of FMC Corporation, Kendall Jones of ProAg and Karen LeVert of Pappas Capital and Ag TechInventures. The trio will be recognized next month at the 11th annual Women in Agribusiness Summit, which will be held in Dallas, September 26-28, at the Hyatt Regency Dallas.

Aktis Oncology Raises $84 Million to Advance Novel Targeted Alpha Radiopharmaceuticals

CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced it has raised a Series A Extension financing of $84 million, bringing the total capital raised to date to $161 million. The extension included participation from new premier healthcare investors Cowen Healthcare Investments, MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc., ArrowMark Partners, Mirae Asset Venture Investment, Timefolio Capital (formerly known as NS Investment), Pappas Capital, and other undisclosed participants. All existing investors MPM Capital, Vida Ventures, EcoR1 Capital, Octagon Capital, TCG Crossover, Bristol Myers Squibb, and Novartis participated in the financing.

Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

CAMBRIDGE, MA -- June 30, 2022 -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for belzupacap sarotalocan (AU-011), Aura’s first VDC product candidate, for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).

Blackford Announces Partnership with Us2.ai For Advanced Echo Interpretation

EDINBURGH, SCOTLAND - JUNE 29, 2022 - Blackford, the platform for medical imaging applications and AI, and Us2.ai today announced their partnership to bring advanced echocardiography analysis tools to the Blackford Platform. The Blackford Platform enables the seamless selection and integration of AI applications into medical imaging workflows, which supports the complex measurement and reporting needs of clinicians.

NuProbe Closes $50M in New Fundraising

Houston, TX, June 02, 2022 (GLOBE NEWSWIRE) -- NuProbe Global, a genomics and molecular diagnostics company, announces the close of its $50M fundraising, co-led by AstraZeneca-CICC Fund, CR-CP Life Science Fund, and Panlin Capital. Existing NuProbe investors Sequoia Capital China, Biotrack Capital, and Yonghua Capital and new investors Pappas Capital, Haoreng Capital, and Deguan Capital also participated in the round. CEC Capital served as the financial advisor for this fundraising. The funds will be used to expand commercial operations, accelerate IVD product clinical studies and regulatory submissions, and develop new genomics and molecular diagnostics technologies.